On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.

On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.